Logo image of NCNA

NUCANA PLC-ADR (NCNA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NCNA - US67022C3043 - ADR

4.17 USD
-0.26 (-5.87%)
Last: 12/5/2025, 8:00:01 PM
4.17 USD
0 (0%)
After Hours: 12/5/2025, 8:00:01 PM
Fundamental Rating

2

Overall NCNA gets a fundamental rating of 2 out of 10. We evaluated NCNA against 535 industry peers in the Biotechnology industry. NCNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NCNA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

NCNA had negative earnings in the past year.
In the past year NCNA has reported a negative cash flow from operations.
NCNA had negative earnings in each of the past 5 years.
NCNA had a negative operating cash flow in each of the past 5 years.
NCNA Yearly Net Income VS EBIT VS OCF VS FCFNCNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of NCNA (-85.16%) is worse than 89.51% of its industry peers.
Looking at the Return On Equity, with a value of -106.15%, NCNA is doing worse than 75.84% of the companies in the same industry.
Industry RankSector Rank
ROA -85.16%
ROE -106.15%
ROIC N/A
ROA(3y)-94.3%
ROA(5y)-72.74%
ROE(3y)-195.95%
ROE(5y)-136.12%
ROIC(3y)N/A
ROIC(5y)N/A
NCNA Yearly ROA, ROE, ROICNCNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

NCNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NCNA Yearly Profit, Operating, Gross MarginsNCNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

5

2. Health

2.1 Basic Checks

The number of shares outstanding for NCNA has been increased compared to 1 year ago.
Compared to 5 years ago, NCNA has more shares outstanding
Compared to 1 year ago, NCNA has an improved debt to assets ratio.
NCNA Yearly Shares OutstandingNCNA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
NCNA Yearly Total Debt VS Total AssetsNCNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

NCNA has an Altman-Z score of 103.82. This indicates that NCNA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of NCNA (103.82) is better than 97.75% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that NCNA is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, NCNA is in line with its industry, outperforming 44.76% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 103.82
ROIC/WACCN/A
WACCN/A
NCNA Yearly LT Debt VS Equity VS FCFNCNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 4.76 indicates that NCNA has no problem at all paying its short term obligations.
NCNA's Current ratio of 4.76 is on the low side compared to the rest of the industry. NCNA is outperformed by 81.46% of its industry peers.
A Quick Ratio of 4.76 indicates that NCNA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.76, NCNA is doing worse than 80.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.76
Quick Ratio 4.76
NCNA Yearly Current Assets VS Current LiabilitesNCNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1

3. Growth

3.1 Past

NCNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.87%, which is quite impressive.
EPS 1Y (TTM)99.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 2.20% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34%
EPS Next 2Y37.55%
EPS Next 3Y20.95%
EPS Next 5Y2.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NCNA Yearly Revenue VS EstimatesNCNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2029 2030 2031 2032 50M 100M 150M
NCNA Yearly EPS VS EstimatesNCNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1K -2K -3K

1

4. Valuation

4.1 Price/Earnings Ratio

NCNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NCNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NCNA Price Earnings VS Forward Price EarningsNCNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NCNA Per share dataNCNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

NCNA's earnings are expected to grow with 20.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.55%
EPS Next 3Y20.95%

0

5. Dividend

5.1 Amount

NCNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

NUCANA PLC-ADR

NASDAQ:NCNA (12/5/2025, 8:00:01 PM)

After market: 4.17 0 (0%)

4.17

-0.26 (-5.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-18 2026-03-18/amc
Inst Owners118.11%
Inst Owner Change-75.46%
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap1.59B
Revenue(TTM)N/A
Net Income(TTM)-27.52M
Analysts82.5
Price TargetN/A
Short Float %0.08%
Short Ratio0.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 46
P/tB 50.26
EV/EBITDA N/A
EPS(TTM)-68.31
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS0.09
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -85.16%
ROE -106.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-94.3%
ROA(5y)-72.74%
ROE(3y)-195.95%
ROE(5y)-136.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.63%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.76
Quick Ratio 4.76
Altman-Z 103.82
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)70.01%
Cap/Depr(5y)101.29%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y34%
EPS Next 2Y37.55%
EPS Next 3Y20.95%
EPS Next 5Y2.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.45%
OCF growth 3YN/A
OCF growth 5YN/A

NUCANA PLC-ADR / NCNA FAQ

What is the ChartMill fundamental rating of NUCANA PLC-ADR (NCNA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NCNA.


Can you provide the valuation status for NUCANA PLC-ADR?

ChartMill assigns a valuation rating of 1 / 10 to NUCANA PLC-ADR (NCNA). This can be considered as Overvalued.


Can you provide the profitability details for NUCANA PLC-ADR?

NUCANA PLC-ADR (NCNA) has a profitability rating of 0 / 10.


What is the financial health of NUCANA PLC-ADR (NCNA) stock?

The financial health rating of NUCANA PLC-ADR (NCNA) is 4 / 10.